Return to List
Study Summary
No.
2008-0851:
.......
Liver; Lung
......
Osama R Mawlawi
......
Imaging Physics
.
Study Summary Title
Study Summary
Number:
2008-0851
Study Title:
Motion Correction of PET Data using Amplitude Gating
.
Physician
New Patient Referral
Name:
Osama R Mawlawi
Patients Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:
Imaging Physics
Referring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:
713-563-2711
Contact us about clinical trials
.
General Information
Disease Group:
Liver
Lung
Supported By:
General Electric Healthcare
Phase of Study:
N/A
Return
Visit:
N/A
Treatment
Agents:
None
Home Care:
N/A
Treatment Loc:
Only at MDACC
Estimated
Length of Stay
in Houston:
N/A
Description/
Intervention:
The goal of this clinical research study is to learn if adjusting the PET
scanner to allow for breathing motion can improve the quality of PET images.
.
Study Objectives / Outcomes
Evaluation of an amplitude based gated Positron Emission Tomography (PET) data acquisition system for all GE Discovery Positron Emission Tomography/ Computed Tomography (PET/CT) scanners.
.
Study Status Information
Study Activation / Registration Date:
03/12/2009
IRB Review and Approval Date:
02/05/2009
Study Type:
Other
Recruitment Status:
Terminated
Projected Accrual:
N/A
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you.
Please Contact the
Referral Office
for more information.
Inclusion Criteria:
1) Patients with lung or liver lesions measuring 0.5-2cm in diameter will be considered.
2) Patients that are scheduled to be imaged in the PET/CT suite at the Mays Building will only be considered.
Exclusion Criteria:
1) Pediatric patients (younger than 18 years) will be excluded.
2) Patients that cannot tolerate being scanned for an additional 10 minutes with arms above their head will be excluded.
.
Links
Registration Number:
NCT00843219
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results
Return to Clinical Trials at M.D. Anderson Cancer Center